A glycoconjugate vaccine for Neisseria meningitidis induces antibodies in human infants that afford protection against meningococcal bacteremia in a neonate rat challenge model

Infection and Immunity

Volumn 70, Issue 12, 2002, Pages 6576-6582

  Mountzouros, Kenneth T ^a   Belanger, Kelly A ^a   Howell, Alan P ^a   Bixler Jr , Garvin S ^a   Madore, Dace V ^a  

^a PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENT COMPONENT C3; IMMUNOGLOBULIN G; MENINGOCOCCUS VACCINE; NEISSERIA MENINGITIDIS GLYCOCONJUGATE VACCINE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBACTERIAL ACTIVITY; ANTIBODY TITER; ARTICLE; BACTEREMIA; BACTERICIDAL ACTIVITY; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; IMMUNIZATION; MENINGOCOCCEMIA; NEISSERIA MENINGITIDIS; NONHUMAN; PASSIVE TRANSPORT; PRIORITY JOURNAL; RAT;

ANIMALS; ANTIBODIES, BACTERIAL; BACTEREMIA; BLOOD BACTERICIDAL ACTIVITY; COMPLEMENT C3; DISEASE MODELS, ANIMAL; HUMANS; IMMUNIZATION, PASSIVE; INFANT, NEWBORN; MENINGOCOCCAL INFECTIONS; MENINGOCOCCAL VACCINES; NEISSERIA MENINGITIDIS, SEROGROUP C; RATS; RATS, SPRAGUE-DAWLEY; VACCINATION; VACCINES, CONJUGATE;

EID: 0036893407     PISSN: 00199567     EISSN: None     Source Type: Journal    
DOI: 10.1128/IAI.70.12.6576-6582.2002     Document Type: Article

References (49)

1. Anderson, E. L., T. Bowers, C. M. Mink, D. J. Kennedy, R. B. Belshe, H. Harakeh, L. Pais, P. Holder, and G. M. Carlone. 1994. Safety and immunogenicity of meningococcal A and C polysaccharide conjugate vaccine in adults. Infect. Immun. 62:3391-3395.
2. Andreoni, J., H. Kayhty, and P. Densen. 1993. Vaccination and the role of capsular polysaccharide antibody in prevention of recurrent meningococcal disease in late complement component-deficient individuals. J. Infect. Dis. 168:227-231.
3. Borrow, R., N. Andrews, D. Goldblatt, and E. Miller. 2001. Serological basis for use of meningococcal serogroup C conjugate vaccines in the United Kingdom: Reevaluation of correlates of protection. Infect. Immun. 69:1568-1573.
4. Borrow, R., A. J. Fox, K. Cartwright, N. T. Begg, and D. M. Jones. 1999. Salivary antibodies following parenteral immunization of infants with a meningococcal serogroup A and C conjugated vaccine. Epidemiol. Infect. 123:201-208.
5. Borrow, R., A. J. Fox, P. C. Richmond, S. Clark, F. Sadler, J. Findlow, R. Morris, N. T. Begg, and K. A. Cartwright. 2000. Induction of immunological memory in UK infants by a meningococcal A/C conjugate vaccine. Epidemiol. Infect. 124:427-432.
6. Bramley, J. C., T. Hall, A. Finn, R. B. Buttery. D. Elliman, S. Lockhart, R. Borrow, and I. G. Jones. 2001. Safety and immunogenicity of three lots of meningococcal serogroup C conjugate vaccine administered at 2, 3 and 4 months of age. Vaccine 19:2924-2931.
7. Campagne, G., A. Garba, P. Fabre, A. Schuchat, R. Ryall, D. Boulanger, M. Bybel, G. Carlone, P. Briantais, B. Ivanoff, B. Xerri, and J. P. Chippaux. 2000. Safety and immunogenicity of three doses of a Neisseria meningitidis A + C diphtheria conjugate vaccine in infants from Niger. Pediatr. Infect. Dis. J. 19:144-150.
8. Choo, S., J. Zuckerman, C. Goilav, E. Hatzmann, J. Everard, and A. Finn. 2000. Immunogenicity and reactogenicity of a group C meningococcal conjugate vaccine compared with a group A + C meningococcal polysaccharide vaccine in adolescents in a randomised observer blind controlled trial. Vaccine 18:2686-2692.
9. Costantino, P., S. Viti, A. Podda, M. A. Velmonte, L. Nencioni, and R. Rappuoli. 1992. Development and phase 1 clinical testing of a conjugate vaccine against meningococcus A and C. Vaccine 10:691-698.
10. Craven, D. E., and C. E. Frasch. 1979. Protection against group B meningococcal disease: Evaluation of serotype 2 protein vaccines in a mouse bacteremia model. Infect. Immun. 26:110-117.
11. English, M., J. M. MacLennan, J. M. Bowen-Morris, J. Deeks, M. Boardman, K. Brown, S. Smith, J. Buttery, J. Clarke, S. Quataert, S. Lockhart, and E. R. Moxon. 2000. A randomised, double-blind, controlled trial of the immunogenicity and tolerability of a meningococcal group C conjugate vaccine in young British infants. Vaccine 19:1232-1238.
12. Fairley, C. K., N. Begg, R. Borrow, A. J. Fox, D. M. Jones, and K. Cartwright. 1996. Conjugate meningococcal serogroup A and C vaccine: Reactogenicity and immunogenicity in United Kingdom infants. J. Infect. Dis. 174:1360-1363.
13. Figueroa, J. E., and P. Densen. 1991. Infectious diseases associated with complement deficiencies. Clin. Microbiol. Rev. 4:359-395.
14. Frantz, I. D. 1942. Growth requirements of the meningococcus. J. Bacteriol. 43:757-761.
15. Frasch, C. E., L. Parkes, R. M. McNelis, and E. C. Gotschlich. 1976. Protection against group B meningococcal disease. I. Comparison of group-specific and type-specific protection in the chick embryo model. J. Exp. Med. 144:319-329.
16. Frasch, C. E., and J. B. Robbins. 1978. Protection against group B meningococcal disease. III. Immunogenicity of serotype 2 vaccines and specificity of protection in a guinea pig model. J. Exp. Med. 147:629-644.
17. Goldschneider, I., E. C. Gotschlich, and M. S. Artenstein. 1969. Human immunity to the meningococcus. I. The role of humoral antibodies. J. Exp. Med. 129:1307-1326.
18. Gonzalez, S., and M. Leinonen. 1991. Neisseria 1990, p. 225-228. In M. Achtman, P. Kohl, C. Marchal, G. Morelli, A. Seiler, and B. Thiesen (ed.), Proceedings of the 7th International Pathogenic Neisseria Conference. Walter de Gruyter & Co., Berlin, Germany.
19. Gotschlich, E. C., T. Y. Liu, and M. S. Artenstein. 1969. Human immunity to the meningococcus. III. Preparation and immunochemical properties of the group A, group B, and group C meningococcal polysaccharides. J. Exp. Med. 129:1349-1365.
20. Granoff, D. M., E. G. Boies, and R. S. Munson. 1984. Immunogenicity of Haemophilus influenzae type b polysaccharide-diphtheria toxoid conjugate vaccine in adults. J. Pediatr. 105:22-27.
21. Granoff, D. M., S. E. Maslanka, G. M. Carlone, B. D. Plikaytis, G. F. Santos, A. Mokatrin, and H. V. Raff. 1998. A modified enzyme-linked immunosorbent assay for measurement of antibody responses to meningococcal C polysaccharide that correlate with bactericidal responses. Clin. Diagn. Lab. Immunol. 5:479-485.
22. Infante, J. F., O. Marrero, S. Sifontes, G. Sierra, C. Campa, E. Caro, M. Gutierrez, A. Malberti, V. Capo, M. Farinas, and E. Munoz. 1994. Evaluation of the efficacy of human antimeningococcal immunoglobulin G in infant rats experimentally infected with Neisseria meningitidis group B. Arch. Med. Res. 25:455-461.
23. Kabat, E. A., and M. M. Mayer. 1961. Experimental Immunochemistry, 2nd Ed. Charles C Thomas, Springfield, Ill.
24. Kellogg, D. S., W. L. Peacock, and W. E. Deacon. 1963. Neisseria gonorrhoeae. I. Virulence genetically linked to clonal variation. J. Bacteriol. 85:1274-1279.
25. Leach, A., P. A. Twumasi, S. Kumah, W. S. Banya, S. Jaffar, B. D. Forrest, D. M. Granoff, D. E. LiButti, G. M. Carlone, L. B. Pais, C. V. Broome, and B. M. Greenwood. 1997. Induction of immunologic memory in Gambian children by vaccination in infancy with a group A plus group C meningococcal polysaccharide-protein conjugate vaccine. J. Infect. Dis. 175:200-204.
26. Lieberman, J. M., S. S. Chiu, V. K. Wong, S. Partridge, S.-J. Chang, C.-Y. Chiu, L. L. Gheesling, G. M. Carlone, and J. I. Ward. 1996. Safety and immunogenicity of a serogroups A/C Neisseria meningitidis oligosaccharide-protein conjugate vaccine in young children. JAMA 275:1499-1503.
27. MacLennan, J., S. Obaro, J. Deeks, D. Lake, C. Elie, G. Carlone, E. R. Moxon, and B. Greenwood. 2001. Immunologic memory 5 years after meningococcal A/C conjugate vaccination in infancy. J. Infect. Dis. 183:97-104.
28. MacLennan, J., S. Obaro, J. Deeks, D. Williams, L. Pais, G. Carlone, R. Moxon, and B. Greenwood. 1999. Immune response to revaccination with meningococcal A and C polysaccharides in Gambian children following repeated immunisation during early childhood. JAMA 17:3086-3093.
29. 197 conjugate vaccine in infants aged 15 to 23 months. Pediatrics 86:527-534.
30. Matthews, N., J. M. Stark, P. S. Harper, J. Doran, and D. M. Jones. 1980. Recurrent meningococcal infections associated with a functional deficiency of the C8 component of human complement. Clin. Exp. Immunol. 39:53-59.
31. Morgan, B. P., and A. Orren. 1998. Vaccination against meningococcus in complement-deficient individuals. Clin. Exp. Immunol. 114:327-329.
32. Mountzouros, K. T., and A. P. Howell. 2000. Detection of complement-mediated antibody-dependent bactericidal activity in a fluorescence-based serum bactericidal assay for group b Neisseria meningitidis. J. Clin. Microbiol. 38:2878-2884.
33. Nassif, X., J. C. Mathison, E. Wolfson, J. A. Koziol, R. J. Ulevitch, and M. So. 1992. Tumour necrosis factor alpha antibody protects against lethal meningococcaemia. Mol. Microbiol. 6:591-597.
34. Nicholson, A., and I. H. Lepoe. 1979. Host defense against Neisseria meningitidis requires a complement-dependent bactericidal activity. Science 205:298-299.
35. Petersen, B. H., T. J. Lee, R. Snyderman, and G. F. Brooks. 1979. Neisseria meningitidis and Neisseria gonorrhoeae bacteremia associated with C6, C7, or C8 deficiency. Ann. Intern. Med. 90:917-920.
36. Ramsay, M. E., N. Andrews, E. B. Kaczmarski, and E. Miller. 2001. Efficacy of meningococcal serogroup C conjugate vaccine in teenagers and toddlers in England. Lancet 357:195-196.
37. Rennels, M. B., K. M. Edwards, H. L. Keyserling, K. Reisinger, M. M. Blatter, S. A. Quataert, D. V. Madore, I. Chang, F. J. Malinoski, J. G. Hackell, and P. R. Paradiso. 2001. Safety and immunogenicity of four doses of Neisseria meningitidis group C vaccine conjugated to CRM197 in United States infants. Pediatr. Infect. Dis. J 20:153-159.
38. Richmond, P., D. Goldblatt, P. C. Fusco, J. D. Fusco, I. Heron, S. Clark, R. Borrow, and F. Michon. 1999. Safety and immunogenicity of a new Neisseria meningitidis serogroup C-tetanus toxoid conjugate vaccine in healthy adults. Vaccine 18:641-646.
39. Ross, S. C., and P. Densen. 1984. Complement deficiency states and infection: Epidemiology, pathogenesis and consequences of neisserial and other infections in an immune deficiency. Medicine 63:243-273.
40. Saukkonen, K. 1988. Experimental meningococcal meningitis in the infant rat. Microb. Pathog. 4:203-211.
41. Saukkonen, K., H. Abdillahi, J. T. Poolman, and M. Leinonen. 1987. Protective efficacy of monoclonal antibodies to class 1 and class 3 outer membrane proteins of Neisseria meningitidis B:15:P1.16 in infant rat infection model: New prospects for vaccine development. Microb. Pathog. 3:261-267.
42. Saukkonen, K., M. Leinonen, H. Abdillahi, and J. T. Poolman. 1989. Comparative evaluation of potential components for group B meningococcal vaccine by passive protection in the infant rat and in vitro bactericidal assay. Vaccine 7:325-328.
43. Saukkonen, K., M. Leinonen, H. Kayhty, H. Abdillahi, and J. T. Poolman. 1988. Monoclonal antibodies to the rough lipopolysaccharide of Neisseria meningitidis protect infant rats from meningococcal infection. J. Infect. Dis. 158:209-212.
44. Schlesinger, M., R. Greenberg, J. Levy, H. Kayhty, and R. Levy. 1994. Killing of meningococci by neutrophils: Effect of vaccination on patients with complement deficiency. J. Infect. Dis. 170:449-453.
45. Sifontes, S., J. F. Infante, P. Perez, E. Caro, G. Sierra, and C. Campa. 1997. The hyperferremic mouse model of the evaluation of the effectiveness of VA-MENGOC-BC against Neisseria meningitidis B clinical isolates. Arch. Med. Res. 28:41-45.
46. Sikkema, D. J., K. E. Friedman, B. Corsaro, A. Kimura, S. W. Hildreth, D. V. Madore, and S. A. Quataert. 2000. Relationship between serum bactericidal activity and serogroup-specific IgG concentration for adults, toddlers and infants immunized with Neisseria meningitidis serogroup C vaccines. Clin. Diagn. Lab. Immunol. 7:764-768.
47. Silverthorne, N. 1937. The bactericidal power of blood and protection against the meningococcal infection. J. Immunol. 33:51-56.
48. Thomas, L., and J. H. Dingle. 1943. Investigations of meningococcal infection. III. The bactericidal action of normal and immune serums for the meningococcus. J. Clin. Investig. 22:375-385.
49. Twumasi, P. A., Jr., S. Kumah, A. Leach, T. J. D. O'Dempsey, S. J. Ceesay, J. Todd, C. V. Broome, G. M. Carlone, L. B. Pais, P. K. Holder, B. D. Plikaytis, and B. M. Greenwood. 1995. A trial of a group A plus group C meningococcal polysaccharide-protein conjugate vaccine in African infants. J. Infect. Dis. 171:632-638.